Nektar reports Q2 2026 results, details Phase 3 rezpegaldesleukin timeline

Nektar Therapeutics reported financial results for the quarter ended June 30, 2026, on August 13, 2026. CEO Howard W. Robin said the company initiated the first Phase 3 ZENITH AD trials in atopic dermatitis in July and plans to start a single registrational Phase 3 study in alopecia areata in early 2027¹. He added that the Phase 3 program establishes a path to the first BLA submission for rezpegaldesleukin in 2029¹.

In its business highlights, Nektar said that in July 2026 it began the first two of its global registrational trials for the ZENITH AD program, testing rezpegaldesleukin in patients with moderate-to-severe atopic dermatitis. The company described the program as consisting of three studies, called "ZENITH AD-1," "ZENITH AD-2," and "ZENITH AD-3," with the first two enrolling patients who have not previously used biologics or systemic JAK inhibitors, and the third enrolling patients who have already been treated with those therapies.

Separately, in April 2026 Nektar reported positive 52-week topline data from the 16-week blinded treatment extension of its Phase 2b "REZOLVE-AA" study, showing that responses to rezpegaldesleukin continued to deepen in patients with severe-to-very-severe alopecia areata who stayed on twice-monthly dosing¹.

On finances, Robin said the company's cash and investments topped one billion dollars at quarter end, with a runway extending into the third quarter of 2028, past the initial Phase 3 data readouts expected in mid-2028¹. Nektar reported cash and investments in marketable securities of $1,023.4 million on June 30, 2026, compared with $245.8 million on December 31, 2025¹. That increase followed an April 2026 underwritten public stock offering that raised $373.8 million in gross proceeds¹.